JRCT ID: jRCT2080224990
Registered date:20/12/2019
Basic Information
Recruitment status | completed |
---|---|
Health condition(s) or Problem(s) studied | |
Date of first enrollment | 29/01/2020 |
Target sample size | 169 |
Countries of recruitment | Japan,Asia except Japan,North America,Europe |
Study type | Interventional |
Intervention(s) | investigational material(s) Generic name etc : INN of investigational material : - Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : control material(s) Generic name etc : INN of investigational material : pembrolizumab Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : |
Outcome(s)
Primary Outcome | safety safety safety safety safety safety pharmacokinetics |
---|---|
Secondary Outcome | efficacy efficacy efficacy efficacy |
Key inclusion & exclusion criteria
Age minimum | >= 20age old |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | |
Exclude criteria |
Related Information
Primary Sponsor | |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) | NCT03260322,2018-001146-34,JapicCTI-195078 |
Contact
Public contact | |
Name | |
Address | |
Telephone | https://www.astellas.com/jp/ja/contact-us |
Affiliation | |
Scientific contact | |
Name | |
Address | |
Telephone | https://www.astellas.com/jp/ja/contact-us |
Affiliation |